Clinical trials Below are current clinical trials.241 studies in Oncology (Medical) (open studies only). Filter this list of studies by location, status and more. A Study to Establish a Living Breast Organoid Biobank for Translational Research Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. Researchers at Mayo Clinic are developing a Biobank of adult stem cell-rich breast organoids, a new research resource to facilitate normal and cancer stem cell research. Subjects in the Biobank will provide samples of excess breast tissue, complete a health questionnaire, and allow access to medical records now and in the future. The Biobank serves as a library for researchers; instead of having to look for volunteers for each new project, researchers can use samples from the Biobank as well as share information already collected. Thoracotomy Versus Thoracoscopic Management Of Pulmonary Metastases In Patients With Osteosarcoma Rochester, Minn. The purpose of this study is to determine if open surgical resection is superior to thoracoscopic resection for thoracic event-free survival (tEFS) in patients with resectable oligometastatic pulmonary osteosarcoma. Furthermore, to determine if open surgical resection is superior to thoracoscopy for event free survival (EFS), for overall survival (OS), and if thoracoscopy is superior to open surgical resection for postoperative pain interference in patients with resectable oligometastatic pulmonary osteosarcoma. A Study Of Nipple Reconstruction Following Post-Mastectomy Breast Reconstruction Jacksonville, Fla. The purpose of this study is to determine what patient or clinical factors are predictive for the choice to have nipple reconstruction or type of nipple reconstruction. Cutaneous Tissue Using Ex Vivo Fluorescence Confocal Microscopy Rochester, Minn. The purpose of this study, as a proof-of-concept, is to investigate whether ex vivo fluorescence microscopy can provide adequate visualization of cutaneous tissue for determination of non-melanoma skin cancer tumor presence in a sample of up to 250 residual skin specimens. Study Of Gastric Cancer And Limited Peritoneal Metastasis Using Robotic Cytoreduction And Hyperthermic Intraperitoneal Chemotherapy Rochester, Minn. The purpose of this study is to assess short-term morbidity and disease-free survival outcomes for patients with gastric adenocarcinoma with limited low volume peritoneal metastasis and/or positive peritoneal cytology undergoing robotic cytoreduction and hyperthermic intraperitoneal chemotherapy. Undiagnosed Tumor/Undifferentiated Mass Registry Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to create a research registry to prospectively collect research biospecimens and corresponding clinical data from subjects with an undiagnosed tumor or undifferentiated mass. Highly Selective CDK7 Inhibitor Q901 In Selected Advanced Solid Tumors Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab Low-grade UTUC Treated With Nadofaragene Firadenovec Administered To Renal Pelvis Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis. A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of GEN3017 as a monotherapy in participants with relapsed or refractory (R/R) CD30-expressing lymphomas. GEN3017 will be administered via subcutaneous injections. All participants will receive active drug; no one will be given placebo. A Study Of A New Way To Treat Children And Young Adults With A Brain Tumor Called NGGCT Rochester, Minn. The purpose of this study is to monitor outcome to ensure that children and young adults with localized central nervous system (CNS) non-germinomatous germ cell tumors (NGGCT) treated with Induction chemotherapy followed by response evaluation and whole ventricular + spinal canal irradiation (WVSCI) will maintain the excellent 2-year progression free survival (PFS) rate as compared to ACNS0122. Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial response (PR) and receive WVSCI as compared to whole ventricular radiation on ACNS1123. Pagination Clinical studies PrevPrevious Page Go to page 88 Go to page 99 Go to page 1010 Go to page 1111 Go to page 1212 NextNext Page Request an appointment Expertise & rankingsResearch Dec. 24, 2024 Share on: FacebookTwitter Mayo Clinic in Rochester, Minnesota, Mayo Clinic in Jacksonville, Florida, and Mayo Clinic in Phoenix/Scottsdale, Arizona, have been recognized among the top Cancer hospitals in the nation by U.S. News & World Report. Learn more about this top honor Oncology (Medical)DepartmenthomeSectionsOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchPatient storiesCosts & insuranceNews from Mayo ClinicReferrals ORG-20180179 Medical Departments & Centers Oncology (Medical)